Physician profile
Richard Roper
NPI 1376545103
$4,110.02
in general payments reported to CMS, 2019-2025
38 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $53.03 · 2021: $399 · 2022: $904 · 2023: $826 · 2024: $692 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $472.56 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $465.48 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $430.56 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $275.20 | 2021-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $273.61 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $262.28 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $255.51 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.09 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $206.92 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Corium, LLC | $186.34 | 2022-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $80.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $76.34 | 2019-2024 | Arexvy, Bexsero, Shingrix |
| Amgen INC. | $75.26 | 2020-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $73.69 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $71.26 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Roper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.